Jones Financial Companies
RARE icon

Jones Financial Companies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jones Financial Companies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Buy
21,279
+4,394
+26% +$109K ﹤0.01% 2093
2026
Q1 		$327K Buy
16,885
+16,541
+4,808% +$372K ﹤0.01% 2219
2025
Q4 		$7.91K Buy
344
+56
+19% +$1.84K ﹤0.01% 3324
2025
Q3 		$8.38K Buy
288
+201
+231% +$6.03K ﹤0.01% 3155
2025
Q2 		$3.18K Sell
87
-8
-8% -$288 ﹤0.01% 3302
2025
Q1 		$3.59K Sell
95
-42
-31% -$1.75K ﹤0.01% 3069
2024
Q4 		$5.76K Buy
137
+109
+389% +$5.41K ﹤0.01% 2712
2024
Q3 		$1.52K Sell
28
-10
-26% -$509 ﹤0.01% 2733
2024
Q2 		$1.56K Buy
+38
New +$1.62K ﹤0.01% 2210

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jones Financial Companies's RARE Position: Q2 2026 in Review

Jones Financial Companies increased its Ultragenyx Pharmaceutical (RARE) stake by 26% in Q2 2026, buying an estimated $109K and bringing the position to 21,279 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Jones Financial Companies first reported a position in RARE in Q2 2024 and has held it in 9 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Jones Financial Companies held 21,279 shares of Ultragenyx Pharmaceutical worth $655K as of Q2 2026.
  • Jones Financial Companies bought 4,394 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $109K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2093 holding.
  • Jones Financial Companies first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 9 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.